Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|12|14|2096-2102

ISSN： 1389-4501

Source： Current Drug Targets, Vol.12, Iss.14, 2011-12, pp. : 2096-2102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 962-968

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Advanced Glycation End Products in Diabetic Neuropathy

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 953-961

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-03 ,pp. : 362-368

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 969-972

Bentham Science Publishers

Access to resources Recommend Favorite